26
|
Son S, Thamlikitkul V, Chokephaibulkit K, Perera J, Jayatilleke K, Hsueh PR, Lu CY, Balaji V, Moriuchi H, Nakashima Y, Lu M, Yang Y, Yao K, Kim SH, Song JH, Kim S, Kim MJ, Heininger U, Chiu CH, Kim YJ. Prospective multinational serosurveillance study of Bordetella pertussis infection among 10- to 18-year-old Asian children and adolescents. Clin Microbiol Infect 2018; 25:250.e1-250.e7. [PMID: 29689428 DOI: 10.1016/j.cmi.2018.04.013] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2018] [Revised: 04/11/2018] [Accepted: 04/16/2018] [Indexed: 12/01/2022]
Abstract
OBJECTIVES Bordetella pertussis continues to cause outbreaks worldwide. To assess the role of children and adolescent in transmission of pertussis in Asia, we performed a multinational serosurveillance study. METHODS From July 2013 to June 2016, individuals aged 10 to 18 years who had not received any pertussis-containing vaccine within the prior year were recruited in 10 centres in Asia. Serum anti-pertussis toxin (PT) IgG was measured by ELISA. Demographic data and medical histories were obtained. In the absence of pertussis immunization, anti-PT IgG ≥62.5 IU/mL was interpreted as B. pertussis infection within 12 months prior, among them levels ≥125 IU/mL were further identified as infection within 6 months. RESULTS A total of 1802 individuals were enrolled. Anti-PT IgG geometric mean concentration was 4.5, and 87 (4.8%) individuals had levels ≥62.5 IU/mL; among them, 73 (83.9%) had received three or more doses of pertussis vaccine before age 6 years. Of 30 participants with persistent cough during the past 6 months, one (3.3%) had level ≥125 IU/mL. There was no significant difference in proportions with anti-PT IgG ≥62.5 IU/mL among age groups (13-15 vs. 10-12 years, 16-18 vs. 10-12 years), between types of diphtheria, pertussis and tetanus (DTP; whole cell vs. acellular), number of doses before age 6 years within the DTP whole-cell pertussis vaccine (five vs. four doses) or acellular pertussis vaccine (five vs. four doses) and history of persistent cough during the past 6 months (yes vs. no). CONCLUSIONS There is significant circulation of B. pertussis amongst Asian children and adolescents, with one in 20 having serologic evidence of recent infection regardless of vaccination background.
Collapse
|
27
|
Murakami K, Hamai S, Moro-Oka T, Okazaki K, Higaki H, Shimoto T, Ikebe S, Nakashima Y. Variable tibiofemoral articular contact stress in fixed-bearing total knee arthroplasties. Orthop Traumatol Surg Res 2018; 104:177-183. [PMID: 29274859 DOI: 10.1016/j.otsr.2017.11.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2017] [Revised: 06/14/2017] [Accepted: 11/17/2017] [Indexed: 02/02/2023]
Abstract
BACKGROUND Rotational allowance at the tibiofemoral joint would be required during deep flexion. However, the amount of flexion and rotation has not been investigated in modern total knee arthroplasty (TKA) designs. The present study aimed to determine the contact stress in five posterior-stabilized fixed-bearing TKA designs. HYPOTHESIS We hypothesized that the contact area and stresses at the tibiofemoral articular surfaces vary according to the type of implant design and tested condition. MATERIALS AND METHODS The contact area and mean and peak contact stresses at the tibiofemoral articular surfaces were determined when a compressive load of 1200N was applied to a NexGen LPS Flex, Scorpio NRG, Genesis II, PFC Sigma, and Foundation implant. Measurements were performed at 0° and 45° flexion with 0°, 5°, 10°, and 15° rotation, and at 90° and 135° flexion with 0, 5°, 10°, 15°, and 20° rotation. RESULTS The LPS Flex showed that the femoral component could not achieve 20° rotation at 135° flexion. The Scorpio NRG showed less than 20MPa of contact stress at all conditions. The Genesis II showed higher contact stress than 20MPa at 135° flexion with 20° rotation. The PFC Sigma showed that the femoral component could not achieve >10° rotation at any flexion angle. The Foundation showed more than 20MPa of contact stress at 90° flexion with 20° rotation and at 135° flexion with 10°, 15°, and 20° rotation. DISCUSSION Surgeons should be more aware of the variable contact conditions of the tibiofemoral articular surfaces in individual TKA designs. LEVEL OF EVIDENCE Level IV, basic science study.
Collapse
|
28
|
Kanegae K, Hiroshige K, Suda T, Iwamoto M, Ohta T, Nakashima Y, Ohtani A. Pharmacokinetics of Bisoprolol and Its Effect on Dialysis Refractory Hypertension. Int J Artif Organs 2018. [DOI: 10.1177/039139889902201204] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The efficacy, safety, and pharmacokinetics of bisoprolol were investigated following oral administration once daily for 12 weeks in hyperreninemic patients with dialysis-refractory hypertension. Mean blood pressure rapidly fell from 132 to 112 mmHg in the 5.0-mg/day (n = 6) and from 142 to 128 mmHg in the 2.5-mg/day patients (n = 5), which were accompanied by a fall in plasma renin activity. On nondialysis days, Cmax and T1/2 were significantly higher in patients than in healthy control subjects. However, Cmax in the 2.5-mg/day patients was almost equal to that in healthy control subjects receiving 5.0 mg/day of bisoprolol. Plasma bisoprolol was dialyzable. During the course of the study, dialysis hypotension and bradycardia occurred in two patients receiving 5.0 mg/day of bisoprolol. In conclusion, a daily dose of 2.5 mg bisoprolol seems to be an adequate and relatively effective dose in our patients with dialysis-refractory hypertension.
Collapse
|
29
|
Kinugasa E, Akizawa T, Nakashima Y, Wakasa M, Koshikawa S. Nafamostat as Anticoagulant for Membrane Plasmapheresis in high Bleeding risk Patients. Int J Artif Organs 2018. [DOI: 10.1177/039139889201501005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Nafamostat mesilate (NM), an ultrashort-acting multi-enzymatic inhibitor, is a useful anticoagulant in high bleeding risk patients needing hemodialysis. We applied NM as a membrane plasmapheresis (MP) anticoagulant in patients with high bleeding risk. Eleven patients, the majority with hepatic failure and active hemorrhagic foci or severe bleeding diathesis, could be treated with MP 22 times under anticoagulation by 20-40 mg/h/NM by continuous infusion without any trouble. Celite-activated coagulation time (CCT) at the plasma separator inlet and outlet was adequately prolonged during MP, but CCT in systemic blood showed no prolongation throughout the procedure, because NM was rapidly inactivated. There was no observable blood coagulation in the extracorporeal circuit including the plasma separator. No adverse reaction or exacerbation of hemorrhage was noted throughout the MP. NM thus appears to be a useful and safe anticoagulant not only for hemodialysis but also for MP in high bleeding risk patients.
Collapse
|
30
|
Cho T, Higaki H, Hirata M, Hojo H, Ichimura M, Ishii K, Itakura A, Katanuma I, Kohagura J, Nakashima Y, Saito T, Tatematsu Y, Yoshikawa M, Itoh H, Minami R, Nagashima S, Numakura T, Watanabe H, Yoshida M, Yatsu K, Miyoshi S. Summarized Scaling Laws of Plasma Confining Potential Formation and Effects in the Gamma 10 Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2018. [DOI: 10.13182/fst03-a11963560] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
31
|
Ogawa T, Kimoto S, Nakashima Y, Furuse N, Ono M, Furokawa S, Okubo M, Yamaguchi H, Kawai Y. Differences in pain thresholds elicited by intraoral electrical stimuli between individuals with and without diabetes mellitus. J Oral Rehabil 2018; 45:235-239. [DOI: 10.1111/joor.12601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2017] [Indexed: 11/30/2022]
|
32
|
Nakashima Y, Niizeki N, Usuki D, Ueno T, Kumagai T. Evaluation of surface roughness of alginate impression materials. Dent Mater 2018. [DOI: 10.1016/j.dental.2018.08.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
33
|
Sonoda K, Motomura G, Ikemura S, Kubo Y, Yamamoto T, Nakashima Y. Effects of intertrochanteric osteotomy plane and preoperative femoral anteversion on the postoperative morphology of the proximal femur in transtrochanteric anterior rotational osteotomy: 3D CT-based simulation study. Orthop Traumatol Surg Res 2017; 103:1005-1010. [PMID: 28782700 DOI: 10.1016/j.otsr.2017.06.012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Revised: 06/11/2017] [Accepted: 06/19/2017] [Indexed: 02/02/2023]
Abstract
BACKGROUND Transtrochanteric anterior rotational osteotomy (ARO) is joint-preserving surgery for patients with osteonecrosis of the femoral head (ONFH). During ARO, femoral neck-shaft varus angulation by changing intertrochanteric osteotomy plane is often designed to obtain a sufficient postoperative intact ratio. However, the effect of intertrochanteric osteotomy plane on postoperative femoral anteversion has not been well examined. Therefore, we performed a simulation study of ARO to determine how intertrochanteric osteotomy plane and preoperative femoral anteversion affect both femoral neck-shaft varus angle and postoperative femoral anteversion. HYPOTHESIS Both femoral neck-shaft varus angle and postoperative femoral anteversion are predicted by intertrochanteric osteotomy plane and preoperative femoral anteversion in ARO. MATERIALS AND METHODS Using CT-data obtained from 10 hips in 10 patients with ONFH, ARO was simulated. On anteroposterior view, basic intertrochanteric osteotomy line (AP-view line) was defined as the perpendicular line to the femoral neck axis. On lateral view, basic intertrochanteric osteotomy line (lateral-view line) made through the cut surface of greater trochanter was defined as the perpendicular line to the lateral axis of the femur. By changing either AP-view or lateral-view line, 49 ARO models/hip were produced, in which femoral neck-shaft varus angle and postoperative femoral anteversion were assessed. RESULTS With increase in the vertically-inclined degree of AP-view line, both neck-shaft varus angle and postoperative femoral anteversion increased. With increase in the posteriorly-tilted degree of lateral-view line, neck-shaft varus angle increased, whereas postoperative femoral anteversion decreased. The approximation equations based on the multiple regression analyses were as follows: neck-shaft varus angle≈vertically-inclined degree of AP-view line×0.9+posteriorly-tilted degree of lateral-view line×0.8+preoperative femoral anteversion×0.7; postoperative femoral anteversion≈vertically-inclined degree of AP-view line×1.1-posteriorly-tilted degree of lateral-view line×0.8. DISCUSSION The postoperative morphology of proximal femur was nearly defined by intertrochanteric osteotomy plane with preoperative femoral anteversion, which is useful for preoperative planning in terms of both achieving a sufficient postoperative intact ratio and maintaining femoral anteversion. LEVEL OF EVIDENCE Level IV case series without control group.
Collapse
|
34
|
Funakoshi H, Sugawara S, Nakashima Y, Homma Y, Mizobe M, Takahashi J, Inoue T, Shiga T, Yasunaga H. 268 The Effectiveness of Fasudil Hydrochloride Administration to Prevent Cerebral Vasospasm After Intervention for Subarachnoid Hemorrhage. Ann Emerg Med 2017. [DOI: 10.1016/j.annemergmed.2017.07.246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
35
|
Oki E, Shimokawa M, Murata A, Takahashi T, Maeda K, Kusumoto T, Munemoto Y, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Saeki H, Saji S, Maehara Y. Effect of lateral lymph node dissection for lower rectal cancer: An ad hoc analysis of the ACTS-RC randomized clinical trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Imai T, Ichimura M, Nakashima Y, Sakamoto M, Katanuma I, Yoshikawa M, Kariya T, Hirata M, Kohagura J, Minami R, Numakura T, Ikezoe R, Oki K, Sakamoto K. GAMMA 10/PDX Project Status and Future. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-1t29] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
37
|
Takeda H, Nakashima Y, Hosoi K, Ichimura K, Furuta T, Tomam M, Hatayama A, Ueda H, Yoshikawa M, Sakamoto M, Ichimura M, Imai T. Numerical Simulation Study for Background Plasma in the GAMMA 10 End-Mirror Cell. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-a16972] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
38
|
Imai T, Ichimura M, Nakashima Y, Katanuma I, Yoshikawa M, Kariya T, Minami R, Miyata Y, Yamaguchi Y, Ikezoe R, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Mutoh T, Sakamoto K, Mizuguchi M, Ota M, Ozawa H, Hosoi K, Yaguchi F, Yonenaga R, Imai Y, Murakani T, Yagi K, Nakamura T, Aoki1 H, Iizumi H, Ishii T, Kondou H, Takeda H, Ichioka N, Masaki S, Yokoyama T. Status and Plan of GAMMA 10 Tandem Mirror Program. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst11-a11563] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
39
|
Furuta T, Takeda H, Toma M, Sato W, Homma Y, Sawada Y, Nakashima Y, Hatayama A. Modeling of Plasma Transport in the Magnetic Mirror Configuration (GAMMA 10). FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-a16971] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
40
|
Cho T, Higaki H, Hirata M, Hojo H, Ichimura M, Ishii K, Islam K, Itakura A, Katanuma I, Kohagura J, Nakashima Y, Numakura T, Saito T, Tatematsu Y, Yoshikawa M, Tokioka S, Yokoyama N, Miyake Y, Tomii Y, Kojima Y, Takemura Y, Imai T, Yoshida M, Sakamoto K, Pastukhov VP, Miyoshi S. Recent Progress in the GAMMA 10 Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst05-a601] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
41
|
Nakashima Y, Sakamoto M, Takeda H, Ichimura K, Hosoi K, Oki K, Yoshikawa M, Nishino N, Matsuura H, Hirata M, Ichimura M, Kariya T, Katanuma I, Kohagura J, Minami R, Numakura T, Ikezoe R, Akabane Y, Kigure S, Nagatsuka Y, Takahashi S, Ueda H, Imai T. First Results and Future Research Plan of Divertor Simulation Experiments Using D-Module in the End-Cell of the GAMMA 10/PDX Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-a16881] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
42
|
Sakamoto M, Oki K, Nakashima Y, Akabane Y, Nagatsuka Y, Yoshikawa M, Nohara R, Hosoi K, Takeda H, Ichimura K, Kohagura J, Yoshikawa M, Ichimura M, Imai T. Plasma Characterization in Divertor Simulation Experiments with a V-Shaped Target on GAMMA 10/PDX. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst13-a16902] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
43
|
Cho T, Higaki H, Hirata M, Hojo H, Ichimura M, Ishii K, Islam K, Itakura A, Katanuma I, Kohagura J, Minami R, Nakashima Y, Numakura T, Saito T, Tatematsu Y, Yoshikawa M, Watanabe O, Kubota Y, Kobayashi T, Yamaguchi Y, Saimaru H, Higashizono Y, Miyata Y, Kiminami S, Shimizu K, Itou M, Ikuno T, Mase A, Yasaka Y, Sakamoto K, Yoshida M, Kojima A, Ogura K, Nishino N, Horton W, Kariya T, Imai T, Pastukhov V, Miyoshi S. Overview of Recent Progress in the GAMMA 10 Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst07-a1305] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
44
|
Tatematsu Y, Saito T, Ikegami H, Sekine T, Nagai D, Nozaki K, Ishii K, Kohagura J, Nakashima Y, Kubo S, Shimozuma T, Cho T. Experiment of Fundamental ECRH in the GAMMA 10 Central Cell. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst05-a656] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
45
|
Nakashima Y, Takeda H, Yonenaga R, Hosoi K, Ozawa H, Ishii T, Nishino N, Ichimura M, Kariya T, Katanuma I, Minami R, Miyata Y, Yamaguchi Y, Yoshikawa M, Imai T. Research Plan for Divertor Simulation Studies and Its Recent Results Using the GAMMA 10 Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst11-a11575] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
46
|
Koga M, Sugano Y, Ueda N, Nakashima Y, Shibata A, Nakayama T, Yokokawa T, Nagai T, Kanzaki H, Yasuda S, Anzai T. P6155Significance of non-thyroidal illness syndrome in patients with dilated cardiomyopathy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Nakashima Y, Sugano Y, Koga M, Shibata A, Ueda N, Nagai T, Kanzaki H, Yasuda S, Anzai T. P707Poor clinical outcome in patients with increased high-sensitive cardiac troponin T in dilated cardiomyopathy: in the context of left ventricular wall stress. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Fukudo S, Matsueda K, Haruma K, Ida M, Hayase H, Akiho H, Nakashima Y, Hongo M. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study. Neurogastroenterol Motil 2017; 29. [PMID: 28205278 DOI: 10.1111/nmo.13023] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 11/17/2016] [Accepted: 12/07/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND Previous studies showed that 5 μg of ramosetron, a serotonin (5-hydroxytryptamine: 5-HT)-3 receptor antagonist, is only effective in male patients with irritable bowel syndrome (IBS) with diarrhea (IBS-D). We hypothesized that either dose 1.25, 2.5, or 5 μg of ramosetron would be effective in female patients with IBS-D. METHODS This randomized, double-blind, placebo-controlled, phase II dose-finding exploratory trial included 409 female outpatients with IBS-D treated in Japan. They were administered oral placebo (n=102), or 1.25 μg (n=104), 2.5 μg (n=104), or 5 μg (n=99) of ramosetron once daily for 12 weeks after a 1-week baseline period. The primary endpoint was monthly responder rates of global improvement of IBS symptoms in the first month. Secondary endpoints included global improvement in the other months, abdominal pain/discomfort, weekly mean changes in the Bristol Stool Form Scale (BSFS), and IBS-QOL. KEY RESULTS Middle dose (2.5 μg) of ramosetron significantly improved abdominal pain/discomfort at second month (62.5%, P=.002), third month (60.6%, P=.005), and the last evaluation point (63.5%, P=.002) and weekly BSFS (P<.05) except at Week 8, 11, and 12 than placebo. IBS-QOL did not change. Ramosetron induced more constipation than placebo. CONCLUSIONS & INFERENCES The trial suggested that 2.5 μg of ramosetron is the most effective and least harmful option for treating female patients with IBS-D (Clinicaltrials.gov ID: NCT01274000).
Collapse
|
49
|
Yoshikawa M, Miyata Y, Mizuguchi M, Imai N, Hojo H, Ichimura M, Kariya T, Katanuma I, Nakashima Y, Minami R, Shidara H, Yamaguchi Y, Shima Y, Ohno Y, Yaguchi F, Imai T. Use of a Gold Neutral Beam Probe to Study Fluctuation Suppression During Potential Formation in the GAMMA 10 Tandem Mirror. FUSION SCIENCE AND TECHNOLOGY 2017. [DOI: 10.13182/fst10-a9492] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
50
|
Sasaki H, Tamura K, Naito Y, Ogata K, Mogi A, Tanaka T, Ikari Y, Masaki M, Nakashima Y, Takamatsu Y. Patient perceptions of symptoms and concerns during cancer chemotherapy: 'affects my family' is the most important. Int J Clin Oncol 2017; 22:793-800. [PMID: 28386794 PMCID: PMC5533818 DOI: 10.1007/s10147-017-1117-y] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2016] [Accepted: 03/23/2017] [Indexed: 11/27/2022]
Abstract
Background Cancer chemotherapy is associated with a variety of side effects/adverse events. It is very important that patients adhere to the planned chemotherapy regimen, which necessitates a minimum of side effects and that these side effects be kept under control. We have investigated patients’ concerns and symptoms during chemotherapy with the aim to seek solutions that will improve patients’ quality of life during chemotherapy. Methods Forty-nine patients with malignant diseases on parenteral antineoplastic agents were sequentially enrolled in this study. These patients completed a questionnaire consisting of 42 items related to non-physical concerns and 52 items of physical symptoms related to chemotherapy. Each patient was also asked to select the three items among these 94 items which affected him/her the most. Results The median age of the cancer patients was 62 years and the male-to-female ratio was 18:31. Among the non-physical concerns, the most frequently chosen concern was ‘affects my family or partner,’ followed by anxiety related to treatment. Regarding the physical symptoms, the most frequent complaints were fatigue, alopecia and constipation, while the most troublesome symptoms were nausea, poor taste and paresthesia. Overall, the most frequently expressed concerns were ‘affects my family or partner’ and anxiety related to treatment. Male patients suffered most from fever, fatigue and nausea, and female patients complained more of poor taste and gastrointestinal problems. Conclusion Patient perceptions of adverse events associated with cancer chemotherapy apparently have changed from physical symptoms to non-physical concerns. In our patient cohort ‘affects my family or partner’ was the most important concern. One important point to note is that female patients often complained of poor taste because this meant they were unable to cook well. Electronic supplementary material The online version of this article (doi:10.1007/s10147-017-1117-y) contains supplementary material, which is available to authorized users.
Collapse
|